Drug Trial Radar · NCT07237256
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,902
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Nov 30, 2033
Study completion Dec 31, 2037
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis; SOLTI Breast Cancer Research Group; GBG Forschungs GmbH; Latin American Cooperative Oncology Group; Gruppo Italiano Mammella (GIM); BOOG Study Center; Canadian Cancer Trials Group; Swiss Cancer Institute; Menarini Silicon Biosystems, INC
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (HR+/HER2-). The NATALEE study showed that the addition of ribociclib for three years to conventional adjuvant hormone therapy (i.e. after surgery) prolonged survival free of invasive disease (i.e. extending to surrounding tissues) in patients with early HR breast cancer+ /HER2-. Unlike other studies, NATALEE included a group of patients at intermediate risk of recurrence, usually treated with adjuvant chemotherapy before receiving hormone therapy. However, the benefit of adjuvant chemotherapy in these patients is uncertain. The hypothesis of the NoLEEta study is that by using the CDK 4/6 inhibitor, patients could avoid adjuvant chemotherapy and therefore be spared the side-effects associated with this chemotherapy, without reducing the efficacy of the treatment.
Conditions
- Breast Cancer
Interventions
Chemotherapy followed by endocrine therapy and ribociclib treatmentDrug
Endocrine therapy and ribociclib treatment
De-escalationOther
De-escalation of the chemotherapy in the adjuvant setting
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer-free survival (iBCFS)Time frame: From ramdomization to iBCFS, up to 12 years.
Locations
138 sites in 5 countries. Site status is shown where the registry gives one.
Clinique de l'Europe
Amiens, France · Not yet recruiting
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France · Not yet recruiting
CH Victor Dupouy
Argenteuil, France · Not yet recruiting
CH Henri Mondor
Aurillac, France · Active not recruiting
Centre Hospitalier d'Auxerre
Auxerre, France · Not yet recruiting
Sainte Catherine - Institut du Cancer Avignon Provence
Avignon, France · Recruiting
Centre Hospitalier de la Cote Basque
Bayonne, France · Active not recruiting
Centre Hospitalier Simone Veil de Beauvais
Beauvais, France · Active not recruiting
Centre Hospitalier Universitaire de Besancon
Besançon, France · Not yet recruiting
Institut Bergonie
Bordeaux, France · Not yet recruiting
Clinique Tivoli
Bordeaux, France · Not yet recruiting
Centre Francois Baclesse
Caen, France · Not yet recruiting
Centre Hospitalier de Carcassonne
Carcassonne, France · Not yet recruiting
Centre Hospitalier William Morey
Chalon-sur-Saône, France · Active not recruiting
Centre Hospitalier Métropole de Savoie
Chambéry, France · Active not recruiting
Centre d'Oncologie et de Radiothérapie 37
Chambray-lès-Tours, France · Not yet recruiting
CH Cholet
Cholet, France · Not yet recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Not yet recruiting
Hospices Civils de Colmar
Colmar, France · Active not recruiting
Polyclinique Saint Côme
Compiègne, France · Not yet recruiting
Clinique de Flandre
Coudekerque-Branche, France · Not yet recruiting
Institut de Cancérologie de Bourgogne
Dijon, France · Not yet recruiting
CHI Fréjus St-Raphaël
Fréjus, France · Active not recruiting
Polyclinique de Blois
La Chaussée-Saint-Victor, France · Not yet recruiting
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France · Not yet recruiting
CHU Grenoble
La Tronche, France · Not yet recruiting
Centre Hospitalier de Versailles
Le Chesnay, France · Not yet recruiting
Centre Hospitalier le Mans
Le Mans, France · Not yet recruiting
Clinique Victor Hugo
Le Mans, France · Not yet recruiting
Polyclinique de Limoges - Site Cinique Chénieux
Limoges, France · Not yet recruiting
Centre Hospitalier Universitaire de Limoges
Limoges, France · Active not recruiting
Centre Leon Berard
Lyon, France · Recruiting
Hôpital Privé Jean Mermoz
Lyon, France · Active not recruiting
Institut Paoli Calmettes
Marseille, France · Not yet recruiting
Centre Hospitalier Annecy Genevois
Metz-Tessy, France · Not yet recruiting
Centre de Cancerologie du Grand Montpellier
Montpellier, France · Recruiting
Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace (GHRMSA)
Mulhouse, France · Recruiting
Hopital Privé du Confluent
Nantes, France · Not yet recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
CHU de NÎMES - Institut de Cancérologie du Gard
Nîmes, France · Not yet recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.